Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

0.1440 +0.0040 (+2.86%)
Streaming Delayed Price Updated: 3:25 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 166,999
Open 0.1400
Bid (Size) 0.1434 (2)
Ask (Size) 0.1496 (36)
Prev. Close 0.1400
Today's Range 0.1400 - 0.1497
52wk Range 0.1207 - 2.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis

Performance

YTD
-63.08%
-63.08%
1 Month
-45.60%
-45.60%
3 Month
-55.83%
-55.83%
6 Month
-61.70%
-61.70%
1 Year
-83.26%
-83.26%

More News

Read More
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via CannabisNewsWire
The Rising Importance Of Minor Cannabinoids In The Growing Edible Market
Via News Direct
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
Via Investor Brand Network
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
Via InvestorPlace
InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference
Via Investor Brand Network
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024
Via InvestorPlace
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results, Business Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer's – New Studies Showcase INM-901's Therapeutic Abilities
Via News Direct
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board
Via Investor Brand Network
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
Via Investor Brand Network
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension
Via Investor Brand Network
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.